Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: The JGOG study

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 127-132

  Umesaki, Naohiko ^a   Fujii, Tuneo ^b   Nishimura, Ryuichiro ^c   Tanaka, Tetsuji ^a   Nishida, Masato ^d   Fushiki, Hiroshi ^e   Takizawa, Ken ^f   Yamamoto, Kaichiro ^g   Hasegawa, Kazuo ^h   Izumi, Rikuichi ⁱ  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b National Kure Hospital   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^d National Hospital Organization Kasumigaura Medical Center   (Japan)

^e TONAMI GENERAL HOSPITAL   (Japan)

^f MITSUI MEMORIAL HOSPITAL   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Kakogawa Japan   (Japan)

ⁱ UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cervical carcinoma; Chemotherapy; CPT 11; MMC

Indexed keywords

IRINOTECAN; MITOMYCIN C;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG RESPONSE; DRUG SCREENING; ENTEROPATHY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; METHODOLOGY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TIME; TOXICITY; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 4644332253     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.06.044     Document Type: Article

References (29)

1. P. Benedetti-Panici, S. Greggi, A. Colombo, M. Amoroso, D. Smaniotto, and D. Giannarelli Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study J. Clin. Oncol. 20 2002 179 188
2. D.S. Alberts, D. Garcia, and N. Mason-Liddil Cisplatin in advanced cancer of the cervix: an update Semin. Oncol. 18 1998 11 24
3. T. Thigpen, R.B. Vance, and T. Khansur The platinum compounds and paclitaxel in the management of patients with carcinoma of the cervix Semin. Oncol. 22 1995 67 72
4. T. Thigpen, R.B. Vance, T. Khansur, and F. Malamud The role of paclitaxel in the management of patients with carcinoma of the cervix Semin. Oncol. 24 1997 41 46
5. D.S. Alberts, R. Kronmal, L.H. Baker, D.L. Stock-Novack, E.A. Surwit, and J.G. Boutselis Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study J. Clin. Oncol. 11 1987 1791 1795
6. E.J. Buxton, C.A. Meanwell, C. Hilton, J.J. Mould, D. Spooner, and A. Chetiyawardana Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer J. Natl. Cancer Inst. 81 1989 359 361
7. S. Takeuchi, K. Dobashi, S. Fujimoto, K. Tanaka, M. Suzuki, and Y. Terashima A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers (in Japanese) Gan To Kagaku Ryoho 18 1991 1681 1689
8. T. Sugiyama, M. Yakushiji, K. Noda, M. Ikeda, R. Kudoh, and A. Yajima Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer Oncology 58 2000 31 37
9. T. Sugiyama, T. Nishida, S. Kumagai, S. Nishio, K. Fujiyoshi, and N. Okura Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer Br. J. Cancer 81 1999 95 98
10. H. Fushiki, T. Hidaka, S. Hori, M. Fujimura, Y. Yamakawa, and R. Izumi Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice (in Japanese) Gan To Kagaku Ryoho 24 1997 1981 1985
11. L.H. Baker, M.I. Opipari, and R.M. Izbicki Phase II study of mitomycin-C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix Cancer 38 1976 2222 2224
12. T. Miyamoto A sequential combination of bleomycin and mitomycin C in the treatment of advanced squamous cancers Recent Results Cancer Res. 63 1978 179 190
13. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am. J. Clin. Oncol. 5 1982 649 655
14. WHO Handbook for reporting results of cancer treatment WHO Offset Publ. vol. 48 1979 World Health Organization Geneva, Switzerland
15. R. Simon Confidence intervals for reporting results of clinical trial Ann. Intern. Med. 105 1986 429 435
16. Y. Kano, K. Suzuki, M. Akutsu, K. Suda, Y. Inoue, and M. Yoshida Effects of CPT-11 in combination with other anti-cancer agents in culture Int. J. Cancer 50 1992 604 610
17. M.A. Villalona-Calero, and J.M. Kolesar Mitomycin as a modulator of irinotecan anticancer activity Oncology 16 2002 21 25
18. T.H. Wasserman, and S.K. Carter The integration of chemotherapy into combined modality treatment of solid tumor: VIII. Cervical cancer Cancer Treat Rev. 4 1997 25 46
19. T. Hata Studies of mitomycin C, especially method of administration Cancer Chemother. Rep. 13 1961 67 77
20. Y. Shimizu, S. Umezawa, and K. Hasumi A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma Ann. Acad. Med. Singap. 27 1998 650 656
21. K. Takizawa, Y. Satow, Y. Kato, and T. Kawana Two patients with ovarian cancer refractory to cisplatin-based chemotherapy managed by a new combination chemotherapy with irinotecan hydrochloride and mitomycin-C Int. J. Clin. Oncol. 2 1997 238 242
22. A.M. Murad, S.A. Triginelli, and J.C.L. Ribalta Phase II trial of bleomycin, Ifosfamide, and carboplatin in metastatic cervical cancer J. Clin. Oncol. 12 1994 55 59
23. H.J. Long, W.G. Cross, H.S. Wieand, M.J. Webb, J.A. Mailliard, and J.W. Kugler Phase II trial of methotreaxate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina Gynecol. Oncol. 57 1995 235 239
24. C.A. Papadimitriou, M.A. Dimopoulos, N. Giannakoulis, K. Sarris, G. Vassilakopoulos, and T. Akrivos Cancer 79 1997 2391 2395
25. J.D. Bloss, J.A. Blessing, B.C. Behrens, R.S. Mannel, J.S. Rader, and A.K. Sood Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group Study J. Clin. Oncol. 20 2002 1832 1837
26. T. Yamao, K. Shirao, Y. Matsumura, K. Muro, Y. Yamada, and M. Goto Phase Iâ€"II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer Ann. Oncol. 12 2001 1729 1735
27. M. Narita, E. Nagai, H. Hagiwara, M. Aburada, T. Yokoi, and T. Kamataki Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate Xenobiotica 23 1993 5 10
28. Y. Sakata, H. Suzuki, and T. Kamataki Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11) Gan To Kagaku Ryoho 21 1994 1241 1244
29. D. Abigerges, J.P. Armand, G.G. Chabot, L. Da Costa, E. Fadel, and C. Cote Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea J. Natl. Cancer Inst. 86 1994 446 449